| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — |
| EBITDA Margin | — | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — | — |
| Current Ratio | — | — | 2.39 | 4.68 | 30.54 | 14.04 | 0.37 |
| Quick Ratio | — | — | 2.39 | 4.68 | 30.54 | 14.04 | 0.37 |
| Debt / Equity | — | — | — | — | — | — | — |
| ROE | -171.23% | -264.20% | 725.14% | -89.43% | -32.56% | -72.43% | 11.55% |
| ROA | -136.87% | -176.58% | -550.58% | -70.31% | -31.49% | -67.27% | -88.71% |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Book Value / Share | 0.82 | 0.76 | -0.86 | 3.47 | 5.83 | 1.20 | — |
Annovis Bio, Inc. is a biopharmaceutical company committed to developing novel therapeutic solutions for neurodegenerative diseases. At the core of its operations is the design of drugs aiming to inhibit neurotoxic protein buildup associated with conditions like Alzheimer's and Parkinson's disease. By targeting the underlying biochemical pathways that lead to such diseases, Annovis Bio seeks to address the cognitive and functional impairments that characterize these neurological disorders. Their focus on creating drugs that have the potential to halt or reverse disease progression places Annovis Bio at the forefront of groundbreaking biomedical research. With these advancements, Annovis Bio is positioned within the specialized biotechnology sector, catering to a critical need in the healthcare market for more effective and innovative treatments. Its contributions are particularly significant as the global demand for solutions for neurodegenerative ailments continues to rise, highlighting its role as an important player in the intersection of health sciences and pharmaceutical innovation.